Pelubiprofen

Drug Profile

Pelubiprofen

Alternative Names: CS 670; DW-330; DW-330SR; Pelubi; Pelubiprofen sustained release; RS 2131

Latest Information Update: 26 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sankyo
  • Developer Daewon Pharmaceutical; Sankyo
  • Class Analgesics; Antipyretics; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Back pain; Osteoarthritis
  • Phase III Fever
  • Phase I Musculoskeletal pain
  • No development reported Rheumatoid arthritis
  • Discontinued Rheumatic disorders

Most Recent Events

  • 07 Mar 2016 Pelubiprofen is still in phase III trials in Fever in South Korea (PO)
  • 01 Mar 2016 Daewon completes a phase-III clinical trial in Fever in South Korea (PO) (NCT01779271)
  • 01 Jun 2014 Daewon Pharmaceutical completes a phase I pharmacokinetics trial in Healthy volunteers in South Korea (NCT02071381)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top